(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029055 A1

(51) International Patent Classification[7]: C07D 487/04, 487/06, 519/00, A61P 29/00

(21) International Application Number: PCT/EP2003/010377

(22) International Filing Date: 18 September 2003 (18.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02021861.6 30 September 2002 (30.09.2002) EP

(71) Applicant *(for all designated States except US)*: **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHIMADA, Mitsuyuki** [JP/JP]; 4-7-905, Kyobatejikatahigashigawa-cho, Nara-shi, Nara 630-8323 (JP). **MURATA, Toshiki** [JP/JP]; 1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267 (JP). **FUCHIKAMI, Kinji** [JP/JP]; 7-1-8-A 103, Umemidai, Kizu-cho, Soraku-gun, Kyoto 619-0215 (JP). **TSUJISHITA, Hideki** [JP/JP]; 1-37-2-522, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0238 (JP). **OMORI, Naoki** [JP/JP]; 1-4-8-A 102, Umemidai, Kizu-cho, Soraku-gun, Kyoto 619-0213 (JP). **KATO, Issei** [JP/JP]; 17-2-202, Surugamachi, Nara-shi, Nara 630-8357 (JP). **MIURA, Mami** [JP/JP]; 1-1365-3-202, Daiwa-cho, Gakuen, Nara 631-0041 (JP). **URBAHNS, Klaus** [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo 657-0024 (JP). **GANTNER, Florian** [AT/JP]; 1-5-40-302, Dogashiba, Tennoji-ku, Osaka-shi, Osaka 540-0033 (JP). **BACON, Kevin** [GB/JP]; 5-15-912, Koyo-cho Naka, Higashinada-ku, Kobe-shi, Hyogo 658-0032 (JP).

(74) Common Representative: **BAYER HEALTHCARE AG**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/029055 A1

(54) Title: FUSED AZOLE-PYRIMIDINE DERIVATIVES

(57) Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with P13K and particularly with P13K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to P13K activity in a human or animal subject.